Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery

Next Previous
Trial Profile

A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Milvexian (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms AXIOMATIC-TKR
  • Sponsors Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag

Most Recent Events

  • 02 Sep 2024 Results PK/PD relationship between aPTT (left) and PT (right) and estimated time-matched plasma concentration, presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
  • 26 Aug 2024 According to a Bristol-Myers Squibb media release, data from this trial will be presented at the European Society of Cardiology (ESC) Congress
  • 15 Nov 2021 According to a Bristol-Myers Squibb media release, data were presented at the American Heart Association (AHA) Scientific Sessions 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top